Managing severe acute respiratory syndrome (SARS) intellectual property rights: the possible role of patent pooling.
Patent applications that incorporate the genomic sequence of the severe acute respiratory syndrome (SARS) coronavirus, have been filed by a number of organizations. This is likely to result in a fragmentation of intellectual property (IP) rights which in turn may adversely affect the development of products, such as vaccines, to combat SARS. Placing these patent rights into a patent pool to be licensed on a non-exclusive basis may circumvent these difficulties and set a key precedent for the use of this form of mechanism in other areas of health care, leading to benefits to public health.
Simon
James H M
JH
CoroNovative BV, Rotterdam, Netherlands. simon@vironovative.com
Claassen
Eric
E
Correa
Carmen E
CE
Osterhaus
Albert D M E
AD
D016915:AIDS Vaccines; D006801:Humans; D018973:Intellectual Property; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D045169:Severe Acute Respiratory Syndrome / Q000235:genetics / Q000276:immunology*
D016915:AIDS Vaccines